Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HTR1B | P28222 | 3/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510942 | 0.83 | ALDH1A1 (0.61) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL238824 | 0.83 | ALDH1A1 (0.61) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL2459518 | 0.82 | HTR7 (0.65) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL30862623 | 0.82 | HTR7 (0.77) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL2456684 | 0.82 | HTR7 (0.77) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL12634482 | 0.82 | DRD2 (0.54) | HTR7ALDH1A1KDM4ESMN1; SMN2ADRB2 | |
| SCHEMBL238407 | 0.82 | HTR7 (0.53) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL7309445 | 0.82 | ADRB2 (0.55) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL29904797 | 0.81 | HTR7 (1.00) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL7821244 | 0.81 | LMNA (0.62) | ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | HTR7 15/4885ALDH1A1 445/4885KDM4E 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.